Compare · GLP-1 agonist
Ecnoglutide vs Tirzepatide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Tirzepatide | |
|---|---|---|
| Evidence | 7/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | A dual GIP/GLP-1 receptor agonist with strong RCT evidence for type 2 diabetes, weight loss, and sleep apnea; GI side effects are common. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (its development name is XW003) is an injectable drug for type 2 diabetes and weight loss. It belongs to the same broad family of medicines as semaglutide — the GLP-1 receptor agonists (drugs that copy a natural gut hormone to lower blood sugar and curb appetite). Two things make it…
Tirzepatide
Tirzepatide is a once-a-week injectable peptide. You may know it by its brand names: Mounjaro (for type 2 diabetes) and Zepbound (for weight management and sleep apnea). Most of the compounds we write about here have thin evidence behind them. This one is different: it has been tested in large,…